官方服务：
资源简介：
Patients 3 and 6 before and after 8 and 16 weeks of treatment
应用场景：
创建时间：
2023-12-27
相关数据集
Supplementary Material for: Focal hypertrichosis during topical tacrolimus therapy for vitiligo: A case report
Introduction: Tacrolimus is widely used in treating vitiligo. Drug-induced hypertrichosis is a well-known side effect of cyclosporine. It is less commonly associated with tacrolimus or with topical ca
DataCite Commons2025-04-05 更新60
Acquired mutations within the JAK2 kinase domain confer resistance to type-I and type-II JAK inhibitors in in vitro models of a high-risk acute lymphoblastic leukemia
Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-risk JAK2-rearranged (JAK2r) B-cell acute lymphoblastic leukemia (B-ALL). Treatment resistance to targeted inhibitors
NIAID Data Ecosystem30
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Figures and Tables
Supplementary Figures 1-7. Supplementary Tables 1-5
NIAID Data Ecosystem10
Betaine protects human melanocytes from H2O2-induced dysfunction and degeneration
Betaine is a potent lipotropic nutrient widely distributed in several foods, involved in protecting various cells against multiple stressful conditions especially oxidative stress. In our study, we de
Mendeley Data2019-07-10 更新30
Management of Vitiligo with Topical JAK Inhibitor Therapy: An Evidence-Based Review
Vitiligo is an acquired progressive skin disorder characterized by hypopigmentation due to absence of functional melanocytes affecting up to 1% of the general population. Initial treatment typically i
NIAID Data Ecosystem20
